Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Statens Serum Institut
ClinicalTrials.gov Identifier:
NCT01642888
First received: July 5, 2012
Last updated: November 18, 2014
Last verified: February 2014
  Purpose

Tuberculosis (TB) continues to be one of the most serious bacterial infections worldwide and therefore new improved diagnostic tests are needed to help doctors in diagnosing TB.

The new skin test is named C-Tb. Like the current tuberculin skin test, PPD, the C-Tb test is injected just under the skin and will, when positive, show redness and/or swelling at the injection site while a negative test will leave no reactions. The investigators hope that this new C-Tb skin test will be more precise (specific) than the PPD test, as the PPD test e.g. may show a reaction if the person tested is BCG vaccinated.

The aim of this trial is to test the C-Tb skin test in volunteers suspected of having TB disease.

With focus on age, HIV status and CD4 count the following analyses are done (in an overall perspective):

  • To compare the C-Tb test to a blood test, the QuantiFERON test.
  • To compare the C-Tb test to the PPD test that is currently being used.
  • To assess the safety of the C-Tb test.

Condition Intervention Phase
Tuberculosis
Biological: C-Tb
Biological: 2 T.U. Tuberculin PPD RT 23 SSI
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: A Phase III Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI (PPD)

Resource links provided by NLM:


Further study details as provided by Statens Serum Institut:

Primary Outcome Measures:
  • To evaluate the diagnostic performance of C-Tb in relation to age, HIV and CD4 counts [ Time Frame: Onset between the injections and 28 days after the injections ] [ Designated as safety issue: No ]
  • To evaluate the clinical safety of C-Tb, with emphasis on children and HIV positive participants [ Time Frame: Onset between the injections and 28 days after the injections ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluate the difference in sensitivity between C-Tb and QuantiFERON®-TB Gold in-Tube in trial participants with confirmed TB diagnosis, overall, and according to age and HIV status. [ Time Frame: From injections to 2-3 days after the injections ] [ Designated as safety issue: No ]
  • To evaluate the difference in sensitivity between C-Tb and Tuberculin PPD RT23 SSI in trial participants with confirmed TB diagnosis overall, and according to age and HIV status. [ Time Frame: Onset between the injections and 28 days after the injections ] [ Designated as safety issue: No ]
  • To evaluate the difference in specificity between C-Tb and QuantiFERON®-TB Gold in-Tube in the control group of 100 children aged 5 - 11 years with no TB symptoms and no known exposure to MTb overall, and according to age. [ Time Frame: From injections to 2-3 days after the injections ] [ Designated as safety issue: No ]
  • To evaluate the difference in specificity between C-Tb and Tuberculin PPD RT23 SSI in the control group of 100 children aged 5 - 11 years with no TB symptoms and no known exposure to MTb overall, and according to age. [ Time Frame: Onset between the injections and 28 days after the injections ] [ Designated as safety issue: No ]
  • To compare the diagnostic outcome of C-Tb to that of QuantiFERON®-TB Gold in-Tube using a latent class approach [ Time Frame: From injections to 2-3 days after the injections ] [ Designated as safety issue: No ]
  • To compare the diagnostic outcome of C-Tb to that of Tuberculin PPD RT23 SSI using a latent class approach [ Time Frame: Onset between the injections and 28 days after the injections ] [ Designated as safety issue: No ]
  • To evaluate the diagnostic performance of Tuberculin PPD RT23 SSI in relation to age, HIV status and CD4 counts [ Time Frame: Onset between the injections and 28 days after the injections ] [ Designated as safety issue: No ]
  • To evaluate the clinical safety of Tuberculin PPD RT23 SSI [ Time Frame: Onset between the injections and 28 days after the injections ] [ Designated as safety issue: Yes ]
  • To evaluate the diagnostic performance of QuantiFERON®-TB Gold in-Tube in relation to age, HIV status and CD4 counts [ Time Frame: On the day of the injections ] [ Designated as safety issue: No ]

Estimated Enrollment: 1175
Study Start Date: September 2012
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 0.1 µg/0.1 mL C-Tb
The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
Biological: C-Tb
The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
Active Comparator: 2 T.U. Tuberculin PPD RT 23 SSI
The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
Biological: 2 T.U. Tuberculin PPD RT 23 SSI
The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme

Detailed Description:

The TESEC-05 trial is an open comparison of the diagnostics performance of C-Tb compared to the QuantiFERON®-TB Gold In-Tube, in combination with a double-blind randomized split-body safety assessment of C-Tb versus to 2 T.U. Tuberculin PPD RT23 SSI.

The trial is a multi-centre Phase III clinical trial designed specifically to address C-Tb in relation to the paediatric population and to HIV infection. The intention is to evaluate how the C-Tb test performs in the paediatric population with respect to safety, and to ensure that SSI will be able to extrapolate data obtained in an adult population to the paediatric population.

Furthermore, the intention is both to evaluate the diagnostic performance and safety of C-Tb in HIV infected individuals and to evaluate whether SSI will be able to extrapolate data obtained in a non-HIV population to a HIV population.

The trial population will consist of paediatric participants with suspected TB infection and adult participants suspected to have TB disease. Furthermore a control group of 100 children between 5 - 11 years of age with no symptoms or known exposure will be recruited from an area with a "low" prevalence of TB (an area with an incidence rate < 299/100,000 per year, the average rate of TB in South Africa in 2005 was 645/100,000 per year.

The trial will be conducted in South Africa where the prevalence of HIV infection is high and MTb infections are endemic.

BCG vaccination at birth has been common practice since 1961 in South Africa. Thus most of the participants are presumed BCG vaccinated.

  Eligibility

Ages Eligible for Study:   up to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

HIV NEGATIVE PARTICIPANTS:

  1. Participants between 5 and 65 years attending the TB clinic due to suspicion of TB disease
  2. Infants, toddlers and children between 28 days and 4 years must either have symptoms or signs of TB or be in close contact to a smear positive pulmonary TB case (more than 6 hours/day for at least five days)
  3. Is between 28 days and 65 years of age
  4. Participant, parent or legal guardian has signed the informed consent
  5. Is HIV negative confirmed by two rapid tests. However, children between 28 days and 4 years may have an unknown HIV status and may receive antiretroviral therapy (ART) or have breastfeeding mothers on ART
  6. Is willing and likely to comply with the trial procedures
  7. Is prepared to grant authorized persons access to their medical record

HIV POSITIVE PARTICIPANTS:

  1. Participants between 5 and 65 years attending the TB clinic due to suspicion of TB disease
  2. Infants, toddlers and children between 28 days and 4 years must either have symptoms* or signs** of TB or be in close contact to a smear positive pulmonary TB case (more than 6 hours/day for at least five days)
  3. Is between 28 days and 65 years of age
  4. Participant, parent or legal guardian has signed the informed consent
  5. Is HIV positive confirmed by:

    1. two positive rapid tests or
    2. 1 positive rapid test and an additional confirmatory ELISA test
  6. A CD4 count has been done
  7. Is willing and likely to comply with the trial procedures
  8. Is prepared to grant authorized persons access to their medical record

HIV NEGATIVE CONTROL GROUP:

  1. Participant with no known contact to people infected with MTb and no signs or symptoms of TB.
  2. Is between 5 and 11 years of age
  3. Participant, parent or legal guardian has signed the informed consent
  4. Is HIV negative confirmed by two rapid tests
  5. Is willing and likely to comply with the trial procedures
  6. Is prepared to grant authorized persons access to their medical record

Exclusion Criteria:

HIV NEGATIVE PARTICIPANTS:

  1. Has a confirmed diagnosis of tuberculosis at Screening Visit
  2. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. MMR, yellow fever, oral typhoid vaccines) except BCG vaccine
  3. Has been tuberculin (TST) tested less than 12 months prior to the day of inclusion
  4. Is pregnant, breastfeeding or intending to get pregnant during the trial period
  5. Is a female of child bearing potential (12 years of age or older) not willing to use effective barrier (including spermicidal gel), hormonal or intrauterine contraceptive measures during the trial period
  6. Has an active disease affecting the lymphoid organs (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)
  7. Has a current skin condition which interferes with the reading of the C-Tb and PPD e.g. tattoos, severe scarring, burns/sunburns, rash, eczema, psoriasis, or any other skin disease at or near the injection sites
  8. Has a condition where blood drawings pose more than minimal risk for the participant, such as haemophilia, other coagulation disorders or significantly impaired venous access
  9. Currently participating in another clinical trial with an investigational or non-investigational drug or device or has participated in another clinical trial within the 3 months prior to dosing
  10. Has participated in previous clinical trials investigating the ESAT-6 and/or CFP-10 antigens
  11. Has a condition which in the opinion of the investigator is not suitable for participation in the trial

HIV POSITIVE PARTICIPANTS:

  1. Has a confirmed diagnosis of tuberculosis at Screening Visit
  2. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. MMR, yellow fever, oral typhoid vaccines)
  3. Has been tuberculin (TST) tested less than 12 months prior to the day of inclusion
  4. Is pregnant, breastfeeding or intending to get pregnant during the trial period
  5. Is a female of child bearing potential (12 years of age or older) not willing to use effective barrier (including spermicidal gel), hormonal or intrauterine contraceptive measures during the trial period
  6. Has an active disease affecting the lymphoid organs except for HIV (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)
  7. Has a known diagnosis of AIDS or is receiving antiviral therapy at the time of Screening Visit
  8. Has a current skin condition which interferes with the reading of the C-Tb and PPD e.g. tattoos, severe scarring, burns/sunburns, rash, eczema, psoriasis, or any other skin disease at or near the injection sites
  9. Has a condition where blood drawings pose more than minimal risk for the participant, such as haemophilia, other coagulation disorders or significantly impaired venous access
  10. Currently participating in another clinical trial with an investigational or non-investigational drug or device or has participated in another clinical trial within the 3 months prior to dosing
  11. Has participated in previous clinical trials investigating the ESAT-6 and/or CFP-10 antigens
  12. Has a condition which in the opinion of the investigator is not suitable for participation in the trial

HIV NEGATIVE CONTROL GROUP:

  1. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. MMR, yellow fever, oral typhoid vaccines) except BCG vaccine
  2. Has been tuberculin (TST) tested less than 12 months prior to the day of inclusion
  3. Has an active disease affecting the lymphoid organs (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)
  4. Has a current skin condition which interferes with the reading of the C-Tb and PPD e.g. tattoos, severe scarring, burns/sunburns, rash, eczema, psoriasis, or any other skin disease at or near the injection sites
  5. Has a condition where blood drawings pose more than minimal risk for the participant, such as haemophilia, other coagulation disorders, or significantly impaired venous access
  6. Currently participating in another clinical trial with an investigational or non-investigational drug or device, or has participated in another clinical trial within the 3 months prior to dosing
  7. Has participated in previous clinical trials investigating the ESAT-6 and/or CFP-10 antigens
  8. Has a condition which in the opinion of the investigator is not suitable for participation in the trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01642888

Locations
South Africa
Primecure Medicentre, Mercantile Hospital
Port Elizabeth, Eastern Cape, South Africa, 6014
Worthwhile Clinical Trials, Lakeview Hospital
Benoni 1501, Gauteng, South Africa, 1501
Setshaba Research Centre
Pretoria, Gauteng, South Africa, 0152
Synexus Stanza Bopape Clinic
Pretoria, Gauteng, South Africa, 0122
Synnyside Medi-Clinic
Pretoria, Gauteng, South Africa, 0002
M2 Karl Bremer Hospital
Bellville, Cape Town, Western Cape, South Africa, 7530
Tiervlei Trial Centre, Karl Bremer Hospital
Bellville, Cape Town, Western Cape, South Africa, 7530
UCT Lung Institute, Groote Schuur Hospital
Cape Town, Western Cape, South Africa, 7925
Be Part Yoluntu Centre
Paarl, Western Cape, South Africa, 7626
Sponsors and Collaborators
Statens Serum Institut
Investigators
Principal Investigator: Andreas Diacon, MD M2 Karl Bremer Hospital
Study Chair: Henrik Aggerbeck, M.Sc. Statens Serum Institut
  More Information

No publications provided

Responsible Party: Statens Serum Institut
ClinicalTrials.gov Identifier: NCT01642888     History of Changes
Other Study ID Numbers: TESEC-05, 2011-005078-40
Study First Received: July 5, 2012
Last Updated: November 18, 2014
Health Authority: European Union: European Medicines Agency

Additional relevant MeSH terms:
Tuberculosis
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections

ClinicalTrials.gov processed this record on November 24, 2014